302 related articles for article (PubMed ID: 22457519)
1. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.
Gorchakov R; Wang E; Leal G; Forrester NL; Plante K; Rossi SL; Partidos CD; Adams AP; Seymour RL; Weger J; Borland EM; Sherman MB; Powers AM; Osorio JE; Weaver SC
J Virol; 2012 Jun; 86(11):6084-96. PubMed ID: 22457519
[TBL] [Abstract][Full Text] [Related]
2. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design.
Gardner CL; Hritz J; Sun C; Vanlandingham DL; Song TY; Ghedin E; Higgs S; Klimstra WB; Ryman KD
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2719. PubMed ID: 24587470
[TBL] [Abstract][Full Text] [Related]
3. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models.
Langsjoen RM; Haller SL; Roy CJ; Vinet-Oliphant H; Bergren NA; Erasmus JH; Livengood JA; Powell TD; Weaver SC; Rossi SL
mBio; 2018 Mar; 9(2):. PubMed ID: 29511072
[TBL] [Abstract][Full Text] [Related]
5. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
6. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.
Silva LA; Khomandiak S; Ashbrook AW; Weller R; Heise MT; Morrison TE; Dermody TS
J Virol; 2014 Mar; 88(5):2385-97. PubMed ID: 24371059
[TBL] [Abstract][Full Text] [Related]
7. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
[TBL] [Abstract][Full Text] [Related]
8. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
Lucas CJ; Davenport BJ; Carpentier KS; Tinega AN; Morrison TE
J Virol; 2022 May; 96(9):e0006422. PubMed ID: 35416719
[TBL] [Abstract][Full Text] [Related]
9. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
[TBL] [Abstract][Full Text] [Related]
10. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
[TBL] [Abstract][Full Text] [Related]
12. Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate.
Plante KS; Rossi SL; Bergren NA; Seymour RL; Weaver SC
PLoS Negl Trop Dis; 2015; 9(9):e0004007. PubMed ID: 26340754
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.
Gardner CL; Burke CW; Higgs ST; Klimstra WB; Ryman KD
Virology; 2012 Apr; 425(2):103-12. PubMed ID: 22305131
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.
Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S
mBio; 2017 Feb; 8(1):. PubMed ID: 28223458
[TBL] [Abstract][Full Text] [Related]
16. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
17. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
[TBL] [Abstract][Full Text] [Related]
19. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
[TBL] [Abstract][Full Text] [Related]
20. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
